Royal Bank Of Canada Issues Positive Forecast for Haleon (LON:HLN) Stock Price

Haleon (LON:HLN) had its target price boosted by equities research analysts at Royal Bank Of Canada from GBX 370 to GBX 390 in a report issued on Tuesday,Digital Look reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 6.89% from the company’s current price.

Several other research firms have also recently commented on HLN. Berenberg Bank lifted their target price on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft upped their target price on Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a report on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research report on Thursday, June 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 400 price target on shares of Haleon in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of GBX 399.

Haleon Stock Performance

LON HLN opened at GBX 364.86 on Tuesday. The company has a market cap of £32.14 billion, a P/E ratio of 20.16, a PEG ratio of 1.49 and a beta of 0.24. The company has a fifty day simple moving average of GBX 352.91 and a 200 day simple moving average of GBX 363.12. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. Haleon has a 12-month low of GBX 317.80 and a 12-month high of GBX 416.10.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. Sell-side analysts predict that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.